Cetuximab and Doxorubicin loaded dextran-coated Fe3O4 magnetic nanoparticles as novel targeted nanocarriers for non-small cell lung cancer

JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS

卷:481

Article

Zhang, Qinlu¹  Liu, Qian²  Du, Menghan²  Vermorken, Alphons²  Cui, Yali²  Zhang, Lixia³  Guo, Lili²  Ma, Le²  Chen, Mingwei¹ 

[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China

[2] Northwest Univ, Natl Engn Res Ctr Miniaturized Detect Syst, Xian 710069, Shaanxi, Peoples R China

[3] Shaanxi Prov Peoples Hosp, Dept Clin Lab, Xian 710069, Shaanxi, Peoples R China

关键词: Nanoparticles;    Drug targeting;    Non-small cell lung cancer;    Cetuximab;    Doxorubicin;    Epidermal growth factor receptor;   

DOI  :  10.1016/j.jmmm.2019.01.021

来源: Elsevier

【 摘 要 】

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer which is the leading cause of cancer death worldwide. Eighty percent of NSCLC patients exhibit high levels of epidermal growth factor receptor (EGFR) expression. In recent years, Doxorubicin (Dox, a widely used chemotherapeutic drug) and/or Cetuximab (Cet, an EGFR-targeted inhibitor) combined with nanoparticles for cancer therapy have attracted significant attention due to their efficient targeting and the resulting increased cytotoxicity on tumor cells. Herein, we report the effects of Dox and Cet, co-conjugated to dextran-coated Fe3O4 magnetic nanoparticles (Dox-NPs-Cet) on the NSCLC cell line A549, which expresses a high level of EGFR. Cytotoxicity, cell proliferation and inter-cellular uptake were investigated after treatment with this conjugate. The results indicate that Dox-NPs-Cet significantly suppress cell proliferation of A549 cells as compared with A549 cells treated with NPs only conjugated with Dox. In summary, our study demonstrates that Dox-NPs-Cet could serve as a promising candidate for targeted therapy of NSCLC.

【 授权许可】

Free